These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 178081)
1. [Drug resistance and hormone dependence of a case of breast cancer]. Di Pietro S; Rovini D Tumori; 1975; 61(6):581-3. PubMed ID: 178081 [TBL] [Abstract][Full Text] [Related]
2. [Ablative hormone therapy and chemotherapy of metastatic breast cancer]. Kasch R; Gerber B; Blaschke U Zentralbl Gynakol; 1989; 111(23):1584-7. PubMed ID: 2560303 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant combination chemotherapy with CMF in primary mammary carcinoma. Veronesi U; Rossi A; Bonadonna G World J Surg; 1977 May; 1(3):337-40. PubMed ID: 883333 [No Abstract] [Full Text] [Related]
4. Adjuvant combination chemotherapy in primary mammary carcinoma: the CMF program. Rossi A; Bonadonna G; Valagussa P; Veronesi U Recent Results Cancer Res; 1977; (62):134-42. PubMed ID: 341246 [No Abstract] [Full Text] [Related]
5. Primary breast cancer: some considerations concerning its management. Fisher B Surg Annu; 1971; 3(0):227-48. PubMed ID: 4367373 [No Abstract] [Full Text] [Related]
6. Letter: Osteoblastic repair of osteolytic tumor metastases following treatment. Elias K JAMA; 1975 Jan; 231(2):135. PubMed ID: 162786 [No Abstract] [Full Text] [Related]
7. [Prospective randomized trial on the efficacy of adjuvant endocrine therapy for ER-positive breast cancer patients after radical mastectomy]. Jiang Z; Song S; Liu X Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):420-2. PubMed ID: 11810777 [TBL] [Abstract][Full Text] [Related]
8. Long-term complete remission of stage IV breast cancer after high-dose chemotherapy and autologous bone marrow transplantation. Dunphy FR; Spitzer G Am J Clin Oncol; 1990 Aug; 13(4):364-6. PubMed ID: 2165740 [No Abstract] [Full Text] [Related]
9. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514 [TBL] [Abstract][Full Text] [Related]
10. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E; Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019 [TBL] [Abstract][Full Text] [Related]
11. Multimodal treatment in operable breast cancer: five-year results of the CMF programme. Rossi A; Bonadonna G; Valagussa P; Veronesi U Br Med J (Clin Res Ed); 1981 May; 282(6274):1427-31. PubMed ID: 6784849 [TBL] [Abstract][Full Text] [Related]
12. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Demicheli R; Miceli R; Moliterni A; Zambetti M; Hrushesky WJ; Retsky MW; Valagussa P; Bonadonna G Ann Oncol; 2005 Sep; 16(9):1449-57. PubMed ID: 15956037 [TBL] [Abstract][Full Text] [Related]
13. [Evaluation of the toxicity of precautional chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in carcinoma of the breast in the first 700 treatment cycles]. Sismondi P; Zola P; Galletto L; De Giovanni D; Giardina G Minerva Ginecol; 1979; 31(7-8):563-8. PubMed ID: 481814 [No Abstract] [Full Text] [Related]
14. [A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective]. Tanaka T; Tanino H; Hirai I; Hata K; Maebeya S; Oota F; Miki Y Gan To Kagaku Ryoho; 2010 Mar; 37(3):511-5. PubMed ID: 20332694 [TBL] [Abstract][Full Text] [Related]
15. [Combination chemotherapy in advanced carcinoma of the breast]. Carmo-Pereira J; Galvão-Teles A; Oliveira Costa F; Bak Gordon R; Henriques E; Dória JM; Freire Cruz M; Silveira Botelho L Arq Patol; 1974; 46(2-3):309-23. PubMed ID: 4458643 [No Abstract] [Full Text] [Related]
16. The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance. Bonadonna G; Rossi A; Valagussa P; Banfi A; Veronesi U Cancer; 1977 Jun; 39(6 Suppl):2904-15. PubMed ID: 326384 [TBL] [Abstract][Full Text] [Related]
17. Letter: Chemotherapy after mastectomy. Cavalli F; Alberto P; Jungi F; Martz G Lancet; 1976 May; 1(7970):1185. PubMed ID: 58229 [No Abstract] [Full Text] [Related]
18. [Chemotherapeutic pathomorphosis of breast cancer]. Frank GA; Volchenko NN; Borisov VI Sov Med; 1990; (11):14-6. PubMed ID: 1963707 [TBL] [Abstract][Full Text] [Related]
19. Surgery and adjuvant chemotherapy in the treatment of operable breast cancer. Rossi A; Valagussa P; Bonadonna G Prog Clin Biol Res; 1977; 12():391-404. PubMed ID: 335401 [No Abstract] [Full Text] [Related]
20. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer. Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]